

LA DISPNEA

Emanuele Pivetta



**UNIVERSITÀ
DI TORINO**



XIII congresso nazionale
simeu
GENOVA 30 MAG - 1 GIU 2024

Medicina d'urgenza - MECAU
Università degli studi di Torino
Città della Salute e della Scienza di Torino

Disclosures

Master in **Epidemiologia**, Università di Torino

R. Fellowship in **emergency ultrasound**, Dept. Of Emergency Medicine, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts


Coordinatore Università di Torino master in **ecografia point-of-care** in medicina d'urgenza e degli stati critici

Butterfly Network, prestito a scopo di ricerca e didattica di butterfly iQ e iQ+




shock

ARDS



dispnea



Dispnea

...

..is the term generally applied to sensations experienced by individuals who complain of unpleasant or uncomfortable respiratory sensations

BLUE Journal, 1999

...but we emphasize strongly that dyspnea [...] can only be perceived by the person experiencing it.

BLUE Journal, 2012

Dispnea



**signs typically evidence of
respiratory distress, such as
tachypnea, use of accessory
muscles, and intercostal retractions**

Dispnea



#1 Ask an unscripted question.

#2 Don't whine.

#3 Count something.

#4 Write something.

#5 Change.



(Atul Gawande, "Better: A Surgeon's Notes on Performance", 2007)

muscles, and intercostal retractions

When a patient presents with dyspnea, the **primary task** of the emergency physician is to assess for **and ensure stability of the patient's airway, breathing, and circulation**. In the case of dyspnea, presentations may range from minor symptoms to extremis.



~ 6 milioni/anno

4.2%/totale

fino al 50%/ tertiary care hospitals



66 European EDs in Belgium ($n=3$), Finland ($n=5$), France ($n=5$), Germany ($n=5$), Italy ($n=1$), the Netherlands ($n=16$), Romania ($n=7$), Spain ($n=1$), Turkey ($n=7$), and UK ($n=16$)

with pediatrics, obstetrics, general medicine, gynecology, various branches of surgery and psychiatry

Qual è il peso della dispnea nei DEA in Italia?

SYSTEM	TYPE OF PROCESS	EXAMPLE OF DISEASE PROCESS	POSSIBLE PRESENTING DYSPNEA SYMPTOMS	POSSIBLE PHYSICAL FINDINGS	POSSIBLE MECHANISMS UNDERLYING DYSPNEA	INITIAL DIAGNOSTIC STUDIES (AND POSSIBLE FINDINGS)
Pulmonary	Airways disease	Asthma, COPD, upper airway obstruction	Chest tightness, tachypnea, increased WOB, air hunger, inability to get a deep breath	Wheezing, accessory muscle use, exertional hypoxemia (especially with COPD)	Increased WOB, hypoxemia, hypercapnia, stimulation of pulmonary receptors	Peak flow (reduced); spirometry (OVD); CXR (hyperinflation; loss of lung parenchyma in COPD), chest CT and airway examination for upper airway obstruction
	Parenchymal disease	Interstitial lung disease ^a	Air hunger, inability to get a deep breath	Dry end-inspiratory crackles, clubbing, exertional hypoxemia	Increased WOB, increased respiratory drive, hypoxemia, hypercapnia, stimulation of pulmonary receptors	Spirometry and lung volumes (RVD); CXR and chest CT (interstitial lung disease)
	Chest wall disease	Kyphoscoliosis, neuromuscular (NM) weakness	Increased WOB, inability to get a deep breath	Decreased diaphragm excursion; atelectasis	Increased WOB; stimulation of pulmonary receptors (if atelectasis is present)	Spirometry and lung volumes (RVD); MIP and MEPs (reduced in NM weakness)
Pulmonary and cardiac	Pulmonary vasculature	Pulmonary hypertension	Tachypnea	Elevated right heart pressures, exertional hypoxemia	Increased respiratory drive, hypoxemia, stimulation of vascular receptors	Diffusion capacity (reduced); ECG; ECHO (to evaluate pulmonary artery pressures) ^b
Cardiac	Left heart failure	Coronary artery disease, cardiomyopathy ^c	Chest tightness, air hunger	Elevated left heart pressures; wet crackles on lung examination; pulsus paradoxus (pericardial disease)	Increased WOB and drive, hypoxemia, stimulation of vascular and pulmonary receptors ^d	Consider BNP testing, especially in the acute setting; ECG, ECHO, may need stress testing and/or LHC
	Pericardial disease	Constrictive pericarditis; cardiac tamponade				
Other	Variable	Anemia Deconditioning Psychological Metabolic disturbances Gastrointestinal (e.g., gastroesophageal reflux disease [GERD], aspiration pneumonitis)	Exertional breathlessness Poor fitness Anxiety	Variable	Metaboreceptors (anemia, poor fitness); chemoreceptors (anaerobic metabolism from poor fitness); some subjects may have increased sensitivity to hypercapnia	Hematocrit for anemia; laboratory studies (e.g., metabolic panel, thyroid hormone testing for metabolic disturbances); consider upper gastrointestinal endoscopy and/or esophageal pH probe testing for GERD and concerns for aspiration; exclude other causes



Point-of-Care Ultrasonography

Visually Satisfying Medicine or Evidence-Based Medicine?


Eden Bernstein, MD; Tracy Y. Wang, MD, MHS, MSc

JAMA Int Med 2021

«We recommend making POCUS use
more evidence-based» for dyspneic
Patients



When a patient presents with dyspnea, the **primary task** of the emergency physician is to assess for **and ensure stability of the patient's airway, breathing, and circulation**. In the case of dyspnea, presentations may range from minor symptoms to extremis.



<https://www.mcgill.ca/about/article/>

William Osler

Da Wikipedia, l'enciclopedia libera.

William Osler (Bond Head, 12 luglio 1849 – Oxford, 29 dicembre 1919) è stato un medico canadese, definito come il padre della medicina moderna. Patologo, educatore, grande bibliofilo, storico e scrittore **Osler è stato anche un rinomato burlone.**

Osler è considerato il creatore dei moderni sistemi di formazione delle specializzazioni mediche.^[1]


Best treatment
is...

Diagnosis, diagnosis, diagnosis!

“medicine is a science of
uncertainty and an art of
probability”

palpazione

auscultazione



insonare



Ispezione

percussione

J. Narula, Y. Chandrashekar, E. Braunwald, JAMA Cardiology 2018

ana mn esi

Part	Description	Manifestations	Examples
Controller	Malfunction presents as abnormal respiratory rate or depth. Often related to abnormal feedback to brain from other parts of the system	Air hunger, need to breathe	Abnormal feedback to brain from other systems. Metabolic acidosis, anxiety
Ventilatory pump	Composed of muscles, nerves that signal the controller, chest wall, and pleura that create negative thoracic pressure, airways and alveoli allowing flow from atmosphere and gas exchange	Increased work of breathing, low tidal volumes	Neuromuscular problems (eg, Guillain-Barré), decreased chest wall compliance, pneumothorax, pneumonia, bronchospasm (COPD, asthma)
Gas exchanger	Oxygen and carbon dioxide cross the pulmonary capillaries in the alveoli. Membrane destruction or interruption of the interface between the gas and capillaries by fluid or inflammatory cells limit gas exchange	Increased respiratory drive, hypoxemia, chronic hypercapnia	Emphysema, pneumonia, pulmonary edema, pleural effusion, hemothorax

ana
mn
esi

Hypercapnia/hypoxia

acute increase of PaCO₂, potentially contributing to dyspnea

common in ARDS, COPD, asthma, acute

ED diagnoses **HF**

Lower respiratory tract infection	1389 (24.9)	616 (20.2)	773 (30.6)	<0.001	0.58 (0.51–0.65)
Heart failure	962 (17.3)	455 (14.9)	507 (20.1)	<0.001	0.63 (0.55–0.73)
COPD exacerbation	882 (15.8)	415 (13.6)	467 (18.5)	<0.001	0.70 (0.60–0.81)
Asthma	584 (10.5)	387 (12.7)	197 (7.8)	<0.001	1.52 (1.27–1.82)
Other	2022 (36.3)	1171 (38.5)	851 (33.7)	<0.001	1.24 (1.10–1.38)

~ 50%

J Emerg Med,
2018

Mechanical loading


hyperinflation (COPD)



Torinoto
day
website

ana
mn
esi

hyperinflation (COPD)



L'utilizzo
dell'ecografia del
diaframma in PS?

Semplice! Non si
usa!



ana
mn
esi

Diagnostic evaluation of dyspnea in ED

Clinical evaluation

Respiratory rate

Signs of *respiratory distress*

- tachypnea
- hyperpnea
- rapid shallow breathing
- activation of accessory muscles

Signs of *increased work of breathing*

- recession of suprasternal fossa
- tracheal tug
- Hoover sign
- sternomastoid activation
- occipital dorsiflexion
- nasal flaring
- mouth opening
- inspiratory laryngeal groans

Blood biomarkers

Arterial blood gas analysis

- pH, PaO₂, and PaCO₂, HCO₃⁻

BNP/pro-BNP

hs-cTn (with a 12-lead ECG)

D-dimer

Imaging


Ultrasound

- heart
- Lung/diaphragm

Chest X-ray

Chest CT (with/without contrast medium)

B



Diaphragmatic Ultrasound Assessment in Subjects With Acute Hypercapnic Respiratory Failure Admitted to the Emergency Department




Respir Care, 2019

hypercapnic AHRF related to COPD exacerbation or pneumonia and requiring NIV

Motion T0-T1-T2 NIV successes > NIV failures

D-US per la gestione della NIV?

Chest, 2017





Potrebbe servire implementare
D-US in PS nel Pz. Disponoico?

GENOVA 30 MAG - 1 GIU 2024

ana
mn
esi

Hypercapnia/hypoxia

acute increase of PaCO₂, potentially contributing to dyspnea

common in ARDS, COPD, asthma, acute

HF

ED diagnoses

Lower respiratory tract infection
Heart failure
COPD exacerbation
Asthma
Other

1389 (24.9)
962 (17.3)
882 (15.8)
584 (10.5)
2022 (36.3)

616 (20.2)
455 (14.9)
415 (13.6)
387 (12.7)
1171 (38.5)

773 (30.6)
507 (20.1)
467 (18.5)
197 (7.8)
851 (33.7)

<0.001 0.58 (0.51–0.65)
<0.001 0.63 (0.55–0.73)
<0.001 0.70 (0.60–0.81)
<0.001 1.52 (1.27–1.82)
<0.001 1.24 (1.10–1.38)

~ 50%

J Emerg Med,
2018

Mechanical loading

hyperinflation (COPD)



Torinoto

*day
website*



Activation of pulmonary receptors

rapid onset dyspnea of unknown origin, disproportionate to the level of blood gases alteration

(PE)

ana
mn
esi

rapid onset dyspnea of unknown origin, disproportionate to the level
of blood gases alteration (PE)



Diagnostic Test Characteristics of FOCUS and Its Components for PE in Subjects With a HR ≥ 100 beats/min and/or sBP < 90 mm Hg
($n = 136$)

	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Positive Likelihood Ratio (95% CI)	Negative Likelihood Ratio (95% CI)
FOCUS	92 (78–98)	64 (53–73)	2.5 (1.9–3.3)	0.13 (0.04–0.38)
TAPSE threshold (cm)				
2.0	88 (72–97)	73 (63–82)	3.3 (2.3–4.7)	0.17 (0.07–0.42)
1.7	66 (48–82)	85 (76–91)	4.5 (2.6–7.6)	0.39 (0.24–0.64)
RVE	51 (34–68)	86 (77–92)	3.6 (2.0–6.3)	0.57 (0.40–0.80)
Septal flattening*	43 (27–61)	93 (86–97)	5.9 (2.7–13.2)	0.61 (0.46–0.82)
TR	50 (26–74)	75 (62–86)	2.0 (1.1–3.8)	0.67 (0.41–1.08)
McConnell's sign†	35 (20–53)	99 (94–100)	33.7 (4.6–249)	0.66 (0.52–0.83)

Esa
me
obi
etti

Symptom

Differential Diagnosis

Variable	qSOFA	SIRS	
	Cut-off	Points	Points
Altered mental status (GCS <15)	Yes	1	—
Heart rate (beats/min)	—	—	>90
Respiratory rate (breaths/min)	≥22	1	>20
Systolic blood pressure (mm Hg)	≤100	1	—
Temperature (°C)	—	—	<36 or >38
White blood cells count (x10 ⁹ /μL)	—	—	<4 or >12 or >10% bands
	Maximum score	3	Maximum score
			4

pulmonary edema

Acute and chronic heart failure, en
(sepsis)

Tachypnea alone

pulmonary embolism, acidosis (including aspirin toxicity), anxiety

Respiratory rate

MEWS & NEWS

Modified Early Warning Score

Score	3	2	1	0	1	2	3
Respiratory rate (min ⁻¹)	≤ 8	9-14	15-20	21-29	> 29		
Heart rate (min ⁻¹)	≤ 40	41-50	51-100	101-110	111-129	> 129	
Systolic BP (mmHg)	≤ 70	71-80	81-100	101-199	≥ 200		
Urine output (ml/kg/h)	Nil	< 0.5					
Temperature (°C)	≤ 35	35.1-36	36.1-38	38.1-38.5	≥ 38.6		
Neurological			Alert	Reacting to voice	Reacting to pain	Unresponsive	

Chart 1: National Early Warning Score (NEWS)

PHYSIOLOGICAL PARAMETERS	3	2	1	0	1	2	3
Respiration Rate	≤8		9 - 11	12 - 20		21 - 24	≥25
Oxygen Saturations	≤91	92 - 93	94 - 95	≥96			
Any Supplemental Oxygen		Yes		No			
Temperature	≤35.0		35.1 - 36.0	36.1 - 38.0	38.1 - 39.0	≥39.1	
Systolic BP	≤90	91 - 100	101 - 110	111 - 219			≥220
Heart Rate	≤40		41 - 50	51 - 90	91 - 110	111 - 130	≥131
Level of Consciousness				A			V, P, or U

The NEWS initiative flowed from the Royal College of Physicians' NEWS2006, and was jointly developed and funded in collaboration with the Royal College of Physicians, Royal College of Nursing, National Outreach Forum and NHS Training for Innovation.

Royal College of Physicians
NHS
Training for Innovation

RDS

	No. of Studies	No. of Patients	% AHF (95% CI)	Sensitivity, % (95% CI)	Specificity, % (95% CI)	LR+ (95% CI)	LR (95% CI)
Symptoms							
Orthopnea ^{7,8,14,16,19,21,36,48,49,53 55,58,60,65}	15	5,430	45.5 (44.2 46.9)	52.1 (50.1 54.0)	70.5 (68.8 72.1)	1.9 (1.4 2.5)	0.74 (0.64 0.85)
PND ^{7,8,14,35,48,51,53,59,64}	9	2,216	44.8 (42.8 46.9)	46.2 (43.7 48.6)	73.9 (71.9 75.9)	1.6 (1.2 2.1)	0.79 (0.71 0.88)
Dyspnea at rest ^{20,51,55,61}	4	2,038	37.9 (35.9 40.0)	54.6 (51.2 58.0)	49.6 (46.9 52.3)	1.1 (0.9 1.4)	0.88 (0.74 1.04)
Absence of productive cough ^{7,8,12,36,49,59,62}	7	2,414	43.0 (41.0 45.0)	82.0 (79.6 84.4)	25.8 (23.5 28.2)	1.13 (1.02 1.26)	0.6 (0.5 0.8)
History							
CRI ^{25,49,55,57,59,61}	6	3,009	42.8 (41.0–44.6)	32.0 (29.4–34.6)	91.4 (90.0–92.7)	3.4 (2.7–4.5)	0.75 (0.71–0.80)
Arrhythmia ^{7,12,18,55,62}	5	3,469	40.2 (38.6–41.9)	38.0 (36.1–40.0)	85.1 (83.9–86.2)	2.7 (2.2–3.4)	0.75 (0.68–0.83)
CHF ^{7,8,14,15,19 21,23,25,36,36,48 50,55,57 61,63,65}	22	8,493	46.0 (44.9–47.0)	55.5 (53.9–57.1)	80.2 (79.0–81.3)	2.7 (2.0–3.7)	0.58 (0.49–0.68)
Renal failure ^{15,18,36,48,50}	5	2,840	40.9 (39.1–42.7)	15.1 (13.1–17.3)	95.1 (94–96.1)	2.3 (1.3–3.9)	0.9 (0.73–1.11)
MI, history of ^{7,15,19,48,49,52,54,55,65}	9	4,208	40.5 (39.1–42.0)	31.8 (29.7–33.9)	87.1 (85.8–88.3)	2.1 (1.8–2.5)	0.82 (0.76–0.89)
AFIB ^{36,49,52 54,65}	6	1,935	51.9 (49.8–54.2)	30.2 (27.4–33.2)	85.3 (82.8–87.5)	2.1 (1.6–2.9)	0.82 (0.71–0.93)
CAD ^{7,14,18,20,21,25,49,55,57–61,63}	14	4,983	42.9 (41.5–44.3)	46.6 (44.5–48.7)	76.2 (74.6–77.7)	2.0 (1.7–2.4)	0.71 (0.64–0.79)
Hyperlipidemia ^{8,49,53,55,68}	5	2,923	39.8 (38.1–41.6)	33.8 (31.1–36.6)	75.3 (73.2–77.3)	1.6 (1.3–1.9)	0.85 (0.82–0.90)
DM ^{8,16,18,19,21,23,25,49,50,52 55,57,59 61,64,65}	19	7,707	47.3 (46.2–48.4)	28.8 (27.4–30.4)	81.7 (80.4–82.8)	1.5 (1.3–1.7)	0.89 (0.84–0.94)
HTN ^{7,8,12,14–16,18,19,21,23,25,36,48–50,53–55,57,58,60,61,63–65}	25	10,137	45.6 (44.6–46.6)	66.9 (65.5–68.3)	50.7 (49.4–52.1)	1.3 (1.3–1.4)	0.62 (0.53–0.73)
No history of COPD ^{7,8,15,18,20,21,23,25,36,48,50,53,55,57–59,61,63}	18	8,053	42.8 (41.7–43.9)	78.9 (77.4–80.3)	34.1 (32.6–35.6)	1.22 (1.11–1.36)	0.7 (0.6–0.8)
Examination findings							
S3 ^{7,8,14,15,20,53–55,67–60,61,65}	14	5,900	45.2 (44.0–46.5)	12.7 (11.5–14.0)	97.7 (97.2–98.2)	4.0 (2.7–5.9)	0.91 (0.88–0.95)
JVD ^{7,8,12,14–16,18,19,21,25,36,48,51,53–55,61–61,64,65}	23	8,012	47.8 (46.7 48.9)	37.2 (35.7 38.7)	87.0 (85.9 88.0)	2.8 (1.7 4.5)	0.76 (0.69 0.84)
Hepatojugular reflex ^{56,59,61,65}	4	1,209	60.4 (57.6 63.1)	14.1 (11.9 16.6)	93.4 (91.2 95.2)	2.2 (1.3 3.7)	0.91 (0.88 0.94)
Leg edema ^{7,8,10,12,14,15,16,18,19 21,23,25,48,49,51,53 55,57 62,65}	26	9,626	47.2 (46.2 48.2)	51.9 (50.5– 53.4)	75.2 (74.0 76.4)	1.9 (1.6 2.3)	0.68 (0.61 0.75)
Murmur ^{7,12,51,54,55,58,62,65}	8	4,004	45.3 (43.8 46.8)	27.8 (25.8 29.9)	83.2 (81.6 84.8)	1.9 (0.9 3.9)	0.93 (0.79 1.08)
Rales ^{7,8,10,12,15,18 21,23,25,36,48,51,53 55,58 61,65}	22	8,775	48.2 (47.1 49.2)	62.3 (60.8 63.7)	68.1 (66.7 69.4)	1.8 (1.5 2.1)	0.60 (0.51 0.69)
Wheezing ^{7,8,12,15,20,23,36,48,53,55,58,59,65}	13	6,970	44.2 (43.0 45.3)	22.3 (20.9 23.8)	64.0 (62.5 65.4)	0.6 (0.5 0.8)	1.19 (1.10 1.30)
Absent fever ^{7,23,36,49,59,62,63}	7	3,197	43.6 (41.9 45.3)	92.4 (90.9 93.8)	20.6 (18.8 22.5)	1.14 (1.02 1.27)	0.4 (0.3 0.6)

AFIB = atrial fibrillation; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; CRI = chronic renal insufficiency; DM = diabetes mellitus; HTN = hypertension; JVD = jugular venous distension; LR = positive likelihood ratio; LR- = negative likelihood ratio; MI = myocardial infarction; PND = paroxysmal nocturnal dyspnea.

Provides additional information about ventilation (Paco_2) to patients with reliable pulse oximetry and bicarbonate level available on BMP

May be faster than general laboratory tests. Useful in assessing anxiety-induced hyperventilation³⁶

Limited evidence for routine use in undifferentiated dyspnea

Emerg Med Clin N Am,
2016

«From a diagnostic point of view, [...], should be always performed in patients with acute dyspnea in the ED.»
Int Emerg Med, 2023

Int Emerg Med,
2023

EGA sopravvalutato? Sempre da fare nel Paziente dispoico?

BNP Value (pg/mL)	Interval LR	N (%)	NT-pro
0–100	0.14 (0.12–0.18)	617 (28)	
100–200	0.29 (0.23–0.38)	308 (14)	
200–300	0.89 (0.67–1.17)	188 (9)	
300–400	1.34 (0.98–1.83)	148 (7)	
400–500	2.05 (1.47–2.84)	148 (7)	
500–600	3.50 (2.30–5.35)	115 (5)	1,1
600–800	4.13 (3.01–5.68)	218 (10)	3,1
800–1,000	5.00 (3.21–7.89)	130 (6)	5,1
1,000–1,500	7.12 (4.53–11.18)	160 (7)	10,1

Recommendations	Class ^a	Level ^b	
BNP/NT-proBNP ^c	I	B	= N-ter
12-lead ECG	I	C	am Find
Transthoracic echocardiography	I	C	%
Chest radiography (X-ray)	I	C	(95
Routine blood tests for comorbidities, including full blood count, urea and electrolytes, thyroid function, fasting glucose and HbA1c, lipids, iron status (TSAT and ferritin)	I	C	42.6 (3 69.4 (6 55.8 (5 60.8 (5 39.6 (3 61.2 (5

Cardiac

Heart failure
ACS
Pulmonary embolism
Myocarditis
Left ventricular hypertrophy
Hypertrophic or restrictive cardiomyopathy
Valvular heart disease
Congenital heart disease
Atrial and ventricular tachyarrhythmias
Heart contusion
Cardioversion, ICD shock
Surgical procedures involving the heart
Pulmonary hypertension

Non-cardiac

Advanced age
Ischaemic stroke
Subarachnoid haemorrhage
Renal dysfunction
Liver dysfunction (mainly liver cirrhosis with ascites)
Paraneoplastic syndrome
COPD
Severe infections (including pneumonia and sepsis)
Severe burns
Anaemia
Severe metabolic and hormone abnormalities
(e.g. thyrotoxicosis, diabetic ketosis)

EHF, 2021


Interstitial edema ^{15,66,72}	3	2,001	48.3 (4
Cephalization ^{8,57,64,66,72}		1,338	54.0 (5
Alveolar edema ^{16,66,72}		2,001	48.3 (4
Pulmonary edema ^{*7,8,12,14,16,18–21,23,36,54,57,58,64}	15	4,393	46.6 (4
Pleural effusion ^{12,20,58,60,72}	5	1,326	55.1 (5
Enlarged cardiac silhouette ^{8,12,15,18,20,21,54,58,60,64,66}	12	3,515	51.7 (4

€ 15,40

LR+ – positive likelihood ratio; LR– – negative likelihood ratio.

*Refers to generalized pulmonary edema in studies that did not report specifically on both “alveolar edema” and “interstitial edema.”

Generation of D-dimer from cross-linked fibrin



Requires risk assessment
and clear clinical
question. Also
increased in
consumptive
coagulopathy,
infection, malignancy,
trauma, dissection,
preeclampsia, and
other cardiovascular
disorders

Emerg Med Clin N Am,
2016

Sensitivity $\geq 95\%$

EJH,
2019

Heart Failure with Preserved Ejection Fraction

A 73-year-old woman with a history of dyspnea on exertion presents for a follow-up visit after hospitalization for acute worsening of dyspnea and orthopnea.

HF with normal natriuretic peptides




Up to 50% of patients with HF have preserved EF

Diastolic dysfunction

Valutare la disfunzione diastolica
ci può servire in PS?

DIASTOLIC HEART FAILURE



In patients with **normal LV EF**

→ qualunque CMP



1-Average $E/e' > 14$
2-Septal e' velocity < 7 cm/s or
Lateral e' velocity < 10 cm/s
3-TR velocity > 2.8 m/s
4-LA volume index > 34 ml/m²

**<50%
positive**

**Normal Diastolic
function**

**50%
positive**


Indeterminate

**>50%
positive**

**Diastolic
Dysfunction**




**EASY
TO USE**



Easy?
Fast?

*... e se ho un Paziente con insufficienza
mitralica ...?*

1, M.D.

ORIGINAL ARTICLE

Open Access

Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system

William Beaubien-Souligny^{1,2*}, Philippe Rola³, Korbin Haycock⁴, Josée Bouchard⁵, Yoan Lamarche⁶, Rory Spiegel⁷ and André Y. Denault^{1,8}


Table 2 Multivariable proportional hazards models to predict acute kidney injury in 145 patients after cardiac surgery using the Venous EXcess UltraSound (VExUS) C grading system

	Crude hazard ratio			Model 1			Model 2		
	HR	CI	p	HR	CI	p	HR	CI	p
VExUS C Grade 0	Reference category			Reference category			Reference category		
VExUS C Grade 1	1.25	0.58–2.66	0.57	1.13	0.52–2.43	0.76	1.13	0.52–2.43	0.76
VExUS C Grade 2	2.65	1.07–6.60	0.036	2.31	0.92–5.80	0.074	2.32	0.92–5.83	0.073
VExUS C Grade 3	3.69	1.65–8.24	0.001	2.83	1.22–6.55	0.015	2.82	1.21–6.55	0.016
Pre-operative AKI risk score [30]	1.02	1.01–1.04	0.001	1.02	1.003–1.03	0.019	1.02	1.003–1.033	0.02
Vasopressor–inotrope score	1.01	0.99–1.03	0.51				1.001	0.98–1.03	0.93

Multivariable proportional hazard regression model (Cox) with the VExUS grade considered as a time-varying covariate (i.e., VExUS grade at day 0 is used to predict AKI at day 1, VExUS grade at day 1 is used for AKI at day 2 and so on). HR hazard ratio, CI 95% confidence intervals

^a Variables included in the multivariate model were the VExUS C grade (segmented time-dependant) and pre-operative AKI risk score [30]

^b Variables included in the multivariate model were the VExUS C grade (segmented time-dependant), vasopressor–inotrope score (segmented time-dependant) and pre-operative AKI risk score [30]



1, M.D.

ORIGINAL ARTICLE

Open Access



Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system

William Beaubien-Souligny^{1,2*}, Philippe Rola³, Korbin Havenock⁴, Insée Bouchard⁵, Yoan L. Amarthe⁶, Rory Spiegel⁷ and André Y. Denault^{1,8}

Operatori neoformati (ma esperti in POCUS)

Table 2 Multivariable proportional hazards models to predict acute kidney injury in 145 patients after cardiac surgery using the Venous EXcess UltraSound (VExUS) C grading system

	Crude hazard ratio								
	HR	CI	p	...	...	...	...	...	...
VExUS C Grade 0	Reference category			Reference category			Reference category		
VExUS C Grade 1	1.25	0.58–2.66	0.57	1.13	0.52–2.43	0.76	1.13	0.52–2.43	0.76
VExUS C Grade 2	2.65	1.07–6.60	0.03						
VExUS C Grade 3	3.69	1.65–8.24	0.00						
Pre-operative AKI risk score [30]	1.02	1.01–1.04	0.00						
Vasopressor-inotrope score	1.01	0.99–1.03	0.5						


Multivariable proportional hazard regression model (Cox) with the VExUS g at day 1, VExUS grade at day 1 is used for AKI at day 2 and so on). HR hazard

^a Variables included in the multivariate model were the VExUS C grade (see

^b Variables included in the multivariate model were the VExUS C grade (see pre-operative AKI risk score [30])

SiM neu

GENOVA 30 MAG - 1 GIU 2024





30 Pazienti


Grade 1	Normal patterns (All three of: I, II, III)	Normal patterns (All three of: I, II, III)	VExUS C	VExUS D	VExUS E
			IVC < 2 cm IVC ≥ 2 cm	Normal patterns (All three of: I, II, III)	Normal patterns or mild abnormalitie(s) (Any combination of: I, II, III, IV, V, VI)
			IVC > 2 cm Severe abnormalities in at least one pattern (At least one of: VII, VIII, IX)	Mild or severe abnormalities in at least one pattern (At least one of: IV, V, VI, VII, VIII, IX)	Severe abnormalities in at least one pattern (At least one of: VII, VIII, IX)
			IVC > 2 cm Severe abnormalities in multiple patterns (At least two of: VII, VIII, IX)	Mild or severe abnormalities in multiple patterns (At least two of: IV, V, VI, VII, VIII, IX)	Severe abnormalities in multiple patterns (At least two of: VII, VIII, IX)


mediana del tempo di durata dell'esame: **34 minuti (IQR 18)**

La VExUs è la panacea per tutti (o quasi) i dubbi nella dispnea?

are observed, while is considered when it is discontinuous with a systolic (S) and diastolic (D) phase, while it is considered diastolic phase seen during the cardiac cycle







78 aa.

Dispnea acuta

...e dolore epigastrico.

Inviata da servizio di emergenza territoriale
per sospetta SCA